ENTA Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (ENTA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $67.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Luly Jay R. | President and CEO | Sell | 4,743 | $14.23 | $67.5K | 858,026 −0.5% of holding | |
| Or Yat Sun | Chief Scientific Officer | Sell | 2,390 | $14.23 | $34.0K | 371,392 −0.6% of holding | |
| Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 2,106 | $14.23 | $30.0K | 30,620 −6.4% of holding | |
| Luu Brendan | Chief Business Officer | Sell | 1,394 | $14.23 | $19.8K | 38,329 −3.5% of holding | |
| Rottinghaus Scott T. | Chief Medical Officer | Sell | 798 | $14.23 | $11.4K | 21,792 −3.5% of holding | |
| Trout Harry R. III | See Remarks | Sell | 542 | $14.23 | $7.7K | 16,348 −3.2% of holding | |
| Capps Kathleen S. | See Remarks | Sell | 323 | $14.23 | $4.6K | 8,377 −3.7% of holding | |
| Trout Harry R. III | See Remarks | Sell | 380 | $13.96 | $5.3K | 16,890 −2.2% of holding | |
| Capps Kathleen S. | See Remarks | Sell | 207 | $13.96 | $2.9K | 8,700 −2.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.